Show simple item record

dc.contributor.authorAdamski, Piotr
dc.contributor.authorSikora, Joanna
dc.contributor.authorLaskowska, Ewa
dc.contributor.authorBuszko, Katarzyna
dc.contributor.authorOstrowska, Małgorzata
dc.contributor.authorUmińska, Julia M
dc.contributor.authorSikora, Adam
dc.contributor.authorSkibińska, Natalia
dc.contributor.authorSobczak, Przemysław
dc.contributor.authorAdamska, Urszula
dc.contributor.authorRość, Danuta
dc.contributor.authorKubica, Aldona
dc.contributor.authorPaciorek, Przemysław
dc.contributor.authorMarszałł, Michał P
dc.contributor.authorNavarese, Eliano P
dc.contributor.authorGorog, Diana A
dc.contributor.authorKubica, Jacek
dc.date.accessioned2018-10-17T15:04:27Z
dc.date.available2018-10-17T15:04:27Z
dc.date.issued2017-10-12
dc.identifier.citationAdamski , P , Sikora , J , Laskowska , E , Buszko , K , Ostrowska , M , Umińska , J M , Sikora , A , Skibińska , N , Sobczak , P , Adamska , U , Rość , D , Kubica , A , Paciorek , P , Marszałł , M P , Navarese , E P , Gorog , D A & Kubica , J 2017 , ' Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction : A prospective, observational, single-centre study ' , PLoS ONE , vol. 12 , no. 10 , e0186013 . https://doi.org/10.1371/journal.pone.0186013
dc.identifier.issn1932-6203
dc.identifier.otherPURE: 13239415
dc.identifier.otherPURE UUID: 8efa01b4-378d-463d-8c0e-1ac3ee349456
dc.identifier.otherPubMed: 29023473
dc.identifier.otherPubMedCentral: PMC5638327
dc.identifier.otherScopus: 85031287218
dc.identifier.urihttp://hdl.handle.net/2299/20717
dc.description© 2017 Adamski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.description.abstractBACKGROUND: Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). METHODS: In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. RESULTS: During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. CONCLUSIONS: Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015).en
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofPLoS ONE
dc.subjectAdenosine
dc.subjectAged
dc.subjectBiological Availability
dc.subjectBlood Platelets
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNon-ST Elevated Myocardial Infarction
dc.subjectPlatelet Aggregation Inhibitors
dc.subjectProspective Studies
dc.subjectPurinergic P2Y Receptor Antagonists
dc.subjectST Elevation Myocardial Infarction
dc.subjectComparative Study
dc.subjectJournal Article
dc.subjectObservational Study
dc.titleComparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction : A prospective, observational, single-centre studyen
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1371/journal.pone.0186013
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record